ReNeuron Group plc Total Voting Rights (1150X)

TIDMRENE

RNS Number : 1150X

ReNeuron Group plc

04 May 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that at 30 April 2021, the Company had 56,863,705 ordinary shares in issue, each carrying one voting right. This follows the issue of 8,000 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.

As the Company holds no ordinary shares in treasury, the figure of 56,863,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

 
 ReNeuron                                                        www.reneuron.com/investors 
 Olav Hellebø, Chief Executive                                         Via Walbrook PR 
  Officer 
 Michael Hunt, Chief Financial Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                         [phone] 
 
 Allenby Capital Limited (Joint Broker) 
  James Reeve/George Payne (Corporate 
  Finance) 
  Tim Sohal (Sales & Corporate Broking)                                 [phone] 
 
 Walbrook PR (Media & Investor Relations)    [phone] or [e-mail] 
                                                          [phone] / +44 (0)7407 
 Paul McManus, Alice Woodings                                                       804 654 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRZZGZDFLFGMZM

(END) Dow Jones Newswires

May 04, 2021 02:00 ET (06:00 GMT)